U.S. markets close in 46 minutes

Amplitude Healthcare Acquisition Corporation (AMHC)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
9.940.00 (0.00%)
As of 9:30AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close9.94
Open9.93
Bid9.92 x 1200
Ask10.00 x 1400
Day's Range9.94 - 9.94
52 Week Range9.70 - 10.50
Volume16
Avg. Volume52,533
Market Cap124.125M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Amplitude Healthcare Acquisition Corp. - AMHC
    PR Newswire

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Amplitude Healthcare Acquisition Corp. - AMHC

    Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Amplitude Healthcare Acquisition Corp. ("AMHC" or the "Company") (NASDAQ: AMHC) relating to its proposed merger with Jasper Therapeutics, Inc. Under the terms of the agreement, AMHC will acquire Jasper through a reverse-merger, with Jasper

  • ACCESSWIRE

    SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Amplitude Healthcare Acquisition Corporation (Nasdaq – AMHC)

    , a biotechnology company focused on hematopoietic cell transplant therapies, and result in Jasper Therapeutics becoming a publicly-listed company. Under the terms of the agreement, Amplitude Healthcare shareholders will retain ownership of only 20.

  • Jasper Therapeutics To List On NASDAQ Via SPAC Reverse Merger
    Benzinga

    Jasper Therapeutics To List On NASDAQ Via SPAC Reverse Merger

    Biotech firm, Jasper Therapeutics Inc, is planning to go public via a reverse SPAC merger deal with Amplitude Healthcare Acquisition Corp (NASDAQ: AMHC) in a $100 million deal. The combined company will be renamed Jasper Therapeutics Inc and its common stock is expected to be listed on NASDAQ under the ticker symbol “JSPR.” The deal also comes with a PIPE financing of an additional $100 million, setting Jasper up with a $490 million market cap once the merger closes in the third quarter of this year. Funds from the SPAC will be used to advance Jasper’s lead program, JSP191, and its stem cell platform. JSP191 is a humanized CD117 monoclonal antibody in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow, creating an empty space for the donor or gene-corrected transplanted stem cells to engraft. It is currently enrolling in two clinical trials for acute myeloid leukemia (AML)/ myelodysplastic syndromes (MDS) and severe combined immunodeficiency (SCID). It is scheduled to start enrollment in 3 additional studies in 2021 for severe autoimmune disease, sickle cell disease, and Fanconi anemia patients undergoing hematopoietic cell transplantation. Price Action: AMHCU shares are up 3.68% at $10.42 during market trading hours on the last check Thursday. See more from BenzingaClick here for options trades from BenzingaGlobal Blood Therapeutics Q1 Earnings Miss Estimates On Disappointing Sales For Its Sickle-Cell Disease DrugBecton Dickinson To Spin-Off Diabetes Care Business: Highlights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.